Clinical Characteristics and Outcome of Primary Hepatic Neuroendocrine Tumors After Comprehensive Therapy

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2020 Oct 2

PMID 33005296

Citations 8

Authors

Hao-Hao Wang

Zhao-Chen Liu

Gong Zhang

Lu-Hao Li

Lin Li

Qing-Bo Meng

Pei-Ju Wang

Dong-Qi Shen

Xiao-Wei Dang

Affiliations

Soon will be listed here.

Abstract

Background: Primary hepatic neuroendocrine tumors (PHNETs), a group of neuroendocrine neoplasms, are extremely rare. There are only few case reports about PHNETs in the literature. The lack of large samples and multicenter research results in poor diagnostic and therapeutic approaches.

Aim: To discuss the clinical characteristics, diagnosis, and treatment of PHNETs and risk factors related to survival.

Methods: We retrospectively analyzed the clinical data, imaging features, immunohistochemistry data, and treatment efficacy of 40 patients who were pathologically diagnosed with PHNETs and admitted to The First Affiliated Hospital of Zhengzhou University from January 1, 2014 to November 15, 2019. Finally, survival analysis was performed to identify the risk factors for survival.

Results: The main symptoms and signs included intermittent abdominal pain (19 patients, 47.5%) and bloating (8 patients, 20.0%). The positive rates of tested tumor markers were recorded as follows: Carbohydrate antigen 19-9 (CA19-9) (6 patients, 15.0%), CA72-4 (3 patients, 7.5%), carcinoembryonic antigen (7 patients, 17.5%), and alpha-fetoprotein (6 patients, 15.0%). Immunohistochemical staining results showed positivity for Syn in 38 (97.4%) of 39 patients, for chromogranin A in 17 (65.4%) of 26 patients, for CD56 in 35 (94.6%) of 37 patients, for AE1/AE3 in 28 (87.5%) of 32 patients, and for Ki-67 in all 40 (100.0%) patients. The overall survival rate was significantly related to the tumor grade, AE1/AE3, and Ki-67. No significant correlation was found between other parameters (age, gender, tumor number, tumor size, metastasis, and treatment) and overall survival.

Conclusion: Higher grade, negative AE1/AE3, and higher Ki-67 are associated with a worse survival rate. Kinds of treatment and other parameters have no significant influence on overall survival.

Citing Articles

Curative resection of multiple primary neuroendocrine tumors enabled by preoperative imaging: a case report.

Shidahara H, Hashimoto M, Mori K, Kuroda S, Tahara H, Kobayashi T J Surg Case Rep. 2025; 2025(1):rjae805.

PMID: 39776832 PMC: 11706000. DOI: 10.1093/jscr/rjae805.

Rare and lacking typical clinical symptoms of liver tumors: Four case reports.

Zhao Y, Bie Y, Zhang G, Feng Y, Wang F World J Gastrointest Oncol. 2024; 16(10):4264-4273.

PMID: 39473954 PMC: 11514678. DOI: 10.4251/wjgo.v16.i10.4264.

Primary Hepatic Neuroendocrine Tumor: A Case Report and Literature Review.

Ghattas S, Al Bitar J, Chahine G, Kamar F, Haddad M, Wakim R Case Reports Hepatol. 2024; 2024:9181560.

PMID: 38440188 PMC: 10911880. DOI: 10.1155/2024/9181560.

Comparison of primary hepatic neuroendocrine tumors and non-hepatitis B non-hepatitis C hepatocellular carcinoma on contrast-enhanced ultrasound.

Tan Z, Li J, Wu Z, Zhou Z, Yang L, Luo Y Front Oncol. 2023; 13:1106281.

PMID: 37492480 PMC: 10364596. DOI: 10.3389/fonc.2023.1106281.

A rare primary hepatic neuroendocrine tumour with laparoscopic resection: a case report.

Alghamdi H J Med Case Rep. 2023; 17(1):296.

PMID: 37386646 PMC: 10311736. DOI: 10.1186/s13256-023-03993-z.

References

Chen Z, Xiao H, Ramchandra P, Huang H . Imaging and pathological features of primary hepatic neuroendocrine carcinoma: An analysis of nine cases and review of the literature. Oncol Lett. 2014; 7(4):956-962. PMC: 3961293. DOI: 10.3892/ol.2014.1844. View

Zhong Q, Chen Q, Xie J, Wang J, Lin J, Lu J . Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Cancer Med. 2018; 7(7):3521-3533. PMC: 6051181. DOI: 10.1002/cam4.1598. View

Iimuro Y, Deguchi Y, Ueda Y, Tanaka A, Iwasa Y, Ishihara M . Primary hepatic carcinoid tumor with metachronous lymph node metastasis after long-term follow up. J Gastroenterol Hepatol. 2002; 17(10):1119-24. DOI: 10.1046/j.1440-1746.2002.02663.x. View

Nakatake R, Ishizaki M, Matui K, Yanagimoto H, Inoue K, Kaibori M . Combination therapies for primary hepatic neuroendocrine carcinoma: a case report. Surg Case Rep. 2017; 3(1):102. PMC: 5593802. DOI: 10.1186/s40792-017-0378-z. View

Sethi S, Kulkarni P . A rare case of a primary hepatic neuroendocrine tumor. Transl Gastroenterol Hepatol. 2017; 1:66. PMC: 5244693. DOI: 10.21037/tgh.2016.06.07. View

Mikolajczak R, Maecke H . Radiopharmaceuticals for somatostatin receptor imaging. Nucl Med Rev Cent East Eur. 2016; 19(2):126-32. DOI: 10.5603/NMR.2016.0024. View

DeLuzio M, Barbieri A, Israel G, Emre S . Two Cases of Primary Hepatic Neuroendocrine Tumors and a Review of the Current Literature. Ann Hepatol. 2017; 16(4):621-629. DOI: 10.5604/01.3001.0010.0313. View

Shinkawa H, Takatsuka S, Kaizaki R, Fujiwara Y, Kurai O, Yamazaki O . Postoperative outcomes of primary hepatic neuroendocrine carcinomas: review article. Osaka City Med J. 2014; 59(2):105-13. View

Song T, Jia Z, Guo X, Zhao H, Bao W, Han D . Does Hepatic Impairment Influence Renal Function Parameters in Liver Cirrhosis?. J Transl Int Med. 2018; 6(2):90-92. PMC: 6032182. DOI: 10.2478/jtim-2018-0017. View

10.

Yao K, Talamonti M, Nemcek A, Angelos P, Chrisman H, Skarda J . Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001; 130(4):677-82; discussion 682-5. DOI: 10.1067/msy.2001.117377. View

11.

Fani M, Nicolas G, Wild D . Somatostatin Receptor Antagonists for Imaging and Therapy. J Nucl Med. 2017; 58(Suppl 2):61S-66S. DOI: 10.2967/jnumed.116.186783. View

12.

Shetty P, Baliga S, Balaiah K, Gnana P . Primary hepatic neuroendocrine tumor: an unusual cystic presentation. Indian J Pathol Microbiol. 2010; 53(4):760-2. DOI: 10.4103/0377-4929.72078. View

13.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

14.

Sotiropoulos G, Charalampoudis P, Delladetsima I, Stamopoulos P, Dourakis S, Kouraklis G . Surgery for giant primary neuroendocrine carcinoma of the liver. J Gastrointest Surg. 2013; 18(4):839-41. DOI: 10.1007/s11605-013-2346-7. View

15.

Kwekkeboom D, Krenning E . Somatostatin receptor imaging. Semin Nucl Med. 2002; 32(2):84-91. DOI: 10.1053/snuc.2002.31022. View

16.

Saeed O, Cramer H, Wang X, Wu H . Fine needle aspiration cytology of hepatic metastases of neuroendocrine tumors: A 20-year retrospective, single institutional study. Diagn Cytopathol. 2017; 46(1):35-39. DOI: 10.1002/dc.23849. View

17.

Zhang W, Luo E, Gan J, Song X, Bao Z, Zhang H . Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound. World J Surg Oncol. 2017; 15(1):122. PMC: 5499042. DOI: 10.1186/s12957-017-1189-1. View

18.

Park C, Chung J, Jang S, Chung M, Bang S, Park S . Clinical features and outcomes of primary hepatic neuroendocrine carcinomas. J Gastroenterol Hepatol. 2012; 27(8):1306-11. DOI: 10.1111/j.1440-1746.2012.07117.x. View

19.

Cives M, Strosberg J . Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018; 68(6):471-487. DOI: 10.3322/caac.21493. View

20.

Lambrescu I, Martin S, Cima L, Herlea V, Badiu C, Fica S . Primary hepatic neuroendocrine tumor after 4 years tumor-free follow-up. J Gastrointestin Liver Dis. 2015; 24(2):241-4. DOI: 10.15403/jgld.2014.1121.242.yrs. View